logo
If You Have a Fear of Deep Water, You Probably Exhibit These 6 Traits, a Psychologist Says

If You Have a Fear of Deep Water, You Probably Exhibit These 6 Traits, a Psychologist Says

Yahoo6 days ago
If You Have a Fear of Deep Water, You Probably Exhibit These 6 Traits, a Psychologist Says originally appeared on Parade.
It's natural to exercise healthy caution and take safety precautions in deep water. You know, wearing a life preserver or not venturing far out in the ocean if a lifeguard isn't on duty. However, some people's fear of deep water runs...deep. They may avoid cruise ships or even sitting by the ocean. People may have one or several reasons for this distress."Some people are afraid of deep water because of a fear of the unknown or the unseen," explains Dr. Brandy Smith, Ph.D., a licensed psychologist specializing in anxiety and coping skills with Thriveworks. "A person may have an active imagination of what could possibly happen or could go wrong. The person may have seen or heard scary things that have happened or could happen in deep water."Fears don't define us—and we can overcome them. However, they can offer clues into our broader personalities. Below, Dr. Smith shares the six telltale traits of people with deep water fears. She also discusses tips for dipping your toes into managing water-related anxiety.Related:
6 Common Personality Traits of People With Fears of Deep Water, a Psychologist Says
1. Struggle with the unknown and unseen
Dr. Smith frequently sees this trait in people who are terrified of deep water. It often stems from a desire to maintain control."This person may have a broader tendency to struggle with the unknown or unseen rather than it being limited to just one area," she says. "The person may like to feel a sense of control over as much as possible within their environment."Related:
2. Avoidance of anxiety-provoking situations
People who are fearful of deep water are often inclined to avoid settings that make them anxious, hoping to circumvent distress. "This could take the form of not being on or around deep water or bodies of water in general," Dr. Smith shares. "It could also involve not watching movies or shows that involve deep water."However, this avoidance becomes a problem if it goes too far and prevents people from participating in fun daily activities. You don't want to be so afraid of sinking that you never try to swim, after all.Related:
3. Overactive imaginations
This one can make navigating life a challenge."Someone with an overactive imagination can generate a wider variety of fearful scenarios, which is not going to help reduce their fear," Dr. Smith says. "This person may also end up being a 'yes, but...' conversationalist if talking with someone who is working to reassure them."So, it could sound like, "Yes, I could go on this boat on a lake, but what if a gust of wind tips it over and we drown?" It might also sound like, "Sure, I could apply for this job, but what if I hate my boss, get fired and wind up drowning in debt?"Related:
4. Stubborn, especially with fears of water
Dr. Smith says people with a deep fear of water may not entertain scenarios involving safe ways to interact with water, such as wearing a life jacket."This person may have a hard time believing that there could be any consistency of safe ways to be within deep water," she explains. "They may have the view that people were 'just lucky' when nothing 'bad' happened."This trait can become extra problematic if water is a regular part of a person's life or if it seeps into other areas, such as driving, attending large gatherings or working in an office above the first floor.Related:
5. They do their research
Education isn't a bad thing. However, Dr. Smith reveals that people with deep-seated fears will often over-educate themselves on what could go wrong."In those times, it can increase the person's anxiety because they are not exposing themselves to a wide enough range of education," she says. "Rather, they are skewing their knowledge to the 'horror' stories of what could or has gone awry before."This overeducation process can have a ripple effect on other, smaller fears. It can prompt people to learn all about the worst-case scenarios, which can worsen these fears, making it hard for them to participate in essential and enjoyable activities, such as attending a pool party or flying to see a friend.
6. Bent on being 'right'—at least about their fear
Again, there's something to be said for having a "healthy" fear of something, like water too deep to stand in. It helps you stay safe. However, people who are hyper-fixated on the trigger can also start to heavily focus on convincing others about how right they are."Realistically, they may occasionally be right about the level of risk, but other times, their fear is disproportionate to the circumstances," Dr. Smith says. "This trait can be encompassed with the sentiment that this person has 'drunk the Kool-Aid' and is working to get other people to 'drink it, too.' This person may think they know the 'truth' about the level of risk and work to convince others about it."However, this one can damage relationships. People may find it annoying or begin to share the irrational fears—and not to their benefit.Related:
3 Tips for Overcoming Fears of Deep Water
1. Wade into it
Dr. Smith says some people benefit from gradually easing into facing their deep-water fears. For instance, you might start in the shallow end of the pool and then progress to deeper waters little by little at a pace that works for you. Related:
2. Explore concerns
Dr. Smith suggests getting curious about your concerns on your own. A support person or mental health provider might also help you identify the reason for your fears."For some people, they learn that some concerns can be addressed with learning more, like educating about how likely something is or is not based on facts and science, which can help reduce their fear," Dr. Smith says.Related:
3. Take precautions to feel safe
Dr. Smith suggests that this step may involve having someone or multiple people accompany you as you expand your comfort zone."You can also consider...a life vest, floats and ropes that give you something to tether to while you stretch yourself to new experiences and depths," Dr. Smith shares.
Up Next:Source:
Dr. Brandy Smith, Ph.D., a licensed psychologist specializing in anxiety and coping skills with Thriveworks
If You Have a Fear of Deep Water, You Probably Exhibit These 6 Traits, a Psychologist Says first appeared on Parade on Aug 1, 2025
This story was originally reported by Parade on Aug 1, 2025, where it first appeared.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Yahoo

time24 minutes ago

  • Yahoo

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Yahoo

time24 minutes ago

  • Yahoo

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Yahoo

time24 minutes ago

  • Yahoo

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store